Service for specialized journalist

Grünenthal Press Releases 2016

Welcome to Grünenthal's Press Overview

27 Sep 2016

A research consortium under the direction of Grünenthal will receive a grant of €1.5 million from the European Fund for Regional Development and the Federal State of North Rhein-Westphalia

  • Research grant awarded by Leitmarktwettbewerb LifeSciences.NRW to improve the development of new analgesic drugs
  • The consortium members, founded and led by Grünenthal, are from the University Hospitals of Cologne and Bonn, and a specialist scientific company, Life & Brain

More ...

23 Jun 2016

EFIC-GRÜNENTHAL GRANT 2016

Aachen/Brussels, 23 June 2016. For the tenth time, young European scientists who have an innovative pain research idea, are called upon to apply for one of the most prestigious and highly regarded pain research grants worldwide: The EFIC-GRÜNENTHAL Grant (E-G-G).

More ...

07 Jun 2016

Grünenthal appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer effective October 1, 2016

Swiss native Gabriel Baertschi follows Prof. Dr. Eric-Paul Pâques who retires after 23 years with the company

Grünenthal Group today announced that its Supervisory Board has named Gabriel Baertschi to become Grünenthal’s new CEO as of October 1, 2016. Gabriel Baertschi will join Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where he currently serves as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques, who has been the CEO of the Grünenthal Group. Grünenthal is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany with affiliates in Europe, Latin America and the U.S. In 2015, Grünenthal achieved revenues of € 1.2 bn.

More ...

02 Jun 2016

Grünenthal and AstraZeneca enter into license agreement for lesinurad in Europe and Latin America

Aachen, June 2, 2016. Grünenthal Group today announced that it has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic™ (lesinurad) in Europe and Latin America. Zurampic™ was approved by the European Medicines Agency (EMA) in February 2016, in combination with a xanthine oxidase inhibitor (XOI), for the treatment of adjunctive hyperuricemia in adult patients with uncontrolled gout.

More ...

11 May 2016

Grünenthal announces exclusive license agreement for commercialization of innovative surgical glue in the EU and Latin America

Agreement underpins Grünenthal’s strategy to strengthen its portfolio for the European hospital market

The Grünenthal Group today announced an exclusive license and supply agreement with Adhesys Medical Inc., USA, on the commercialization of an innovative topical skin adhesive. With this agreement, Grünenthal acquires the exclusive distribution rights for the EU and Latin American markets. Both companies pursue the common objective to launch a medical device that meets highest standards.

More ...

15 Mar 2016

Grünenthal Group to Acquire Almirall de Mexico, S.A. de C.V.

Aachen, Germany and Mexico City, Mexico, March 15, 2016. Grünenthal Group announced today to have entered into a definitive agreement with Almirall Group under which Grünenthal will acquire 100% of the share capital of Almirall de Mexico. The transaction also includes an agreement to perpetually license a portfolio of mainly international products with around 17.5 million Euro net sales in 2015 in Mexico. The transaction will be completed in early May, 2016.

More ...

03 Mar 2016

Drug Discovery Collaboration between Grünenthal and Axxam

Grünenthal capitalizes on Axxam’s drug discovery platform and expertise to identify small molecule lead structures for its early pipeline in pain and inflammation

Grünenthal and Axxam announced today that they have entered into an integrated collaboration. The objective is to discover novel small molecule lead structures for the development of pain and inflammation therapeutics by combining Axxam’s drug discovery platform with Grünenthal’s expertise on emerging and innovative biological pathways and targets.

More ...

22 Feb 2016

PATHEON SELECTED BY GRÜNENTHAL TO DEVELOP DRUGS USING INTAC® ABUSE DETERRENT FORMULATIONS TECHNOLOGY

Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in Aachen, Germany to serve as its preferred development partner for its products made using Grünenthal’s innovative abuse deterrent formulation technology INTAC®.

More ...

10 Feb 2016

Grünenthal sets a strong sign of commitment for the future of their Research & Development

Inauguration of new research building on Grünenthal Campus in Aachen

The Grünenthal Group announced today the completion and inauguration of its new research building on the Grünenthal Campus in Aachen. It will accommodate room for 150 employees working in research and development. Thus Grünenthal again commits to its headquarters in Aachen and to researching and developing of innovative medicines to the benefits of patients. The annual Research & Development expenditures of the group have constantly been well above the pharmaceutical industry’s average for years in relation to sales. The Grünenthal Campus in Aachen has been continuously enlarged since 2011. In the last five years, the company has invested 131 million Euros for real estate, buildings and production sites.

More ...

08 Jan 2016

Grünenthal and Akashi Therapeutics Inc. announce joint drug development program for HT-100 in the treatment of patients with Duchenne Muscular Dystrophy (DMD)

  • HT-100 is an orally available small molecule drug candidate designed to reduce fibrosis and inflammation and to promote healthy muscle fiber regeneration in patients with DMD
  • DMD is a rare, yet the most common fatal genetic disorder diagnosed in childhood. Today, no curative treatment exists, and patients typically die in their twenties

More ...

next [1]